
UCB reports positive results for neurodevelopmental disorder
Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD). The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA. The results… Read More














